REFERENCES
1 17th World Conference on Tobacco or Health. Cape Town Declaration on
Human Rights and a Tobacco-free World.https://unfairtobacco.org/en/cape-town-declaration/2018
2 Murray CJL, Aravkin AY, Zheng P, et al. Global burden of 87 risk
factors in 204 countries and territories, 1990–2019: a
systematic analysis for the Global Burden of Disease Study 2019.The Lancet 2020; 396 :1223-1249
3 Zafeiridou M, Hopkinson NS, Voulvoulis N. Cigarette Smoking: An
Assessment of Tobacco’s Global Environmental Footprint Across Its Entire
Supply Chain. Environmental Science & Technology 2018;52 :8087-8094
4 UN Development Programme. The WHO Framework Convention on Tobacco
Control an Accelerator for Sustainable Development.http://www.undp.org/content/undp/en/home/librarypage/hiv-aids/-the-who-framework-convention-on-tobacco-control-an-accelerator-.html2017
5 European Respiratory Society. ERS response to the proposed acquisition
of Vectura by Philip Morris International.https://www.ersnet.org/news-and-features/news/ers-response-to-the-proposed-acquisition-of-vectura-by-philip-morris-international/2021
6 British Thoracic Society. BTS statement: Proposed takeover of Vectura
by Philip Morris International.https://www.brit-thoracic.org.uk/news/2021/bts-statement-proposed-takeover-of-vectura-by-philip-morris-international/2021
7 Vectura. Vectura PLC - Track Record.https://www.vectura.com/about-vectura/track-record/
(acccessed 20-8-21) 2021
8 Vectura. Vectura Group plc Annual Report and Accounts 2020.https://www.vectura.com/wp-content/uploads/2021/04/Vectura-Group-plc-Annual-Report-and-Accounts-2020.pdf
(accessed 20-8-21) 2021
9 National Institute for Clinical Excellence. Shared decision making -
NICE guideline [NG197]https://www.nice.org.uk/guidance/NG197 2021
10 Usmani O, Capstick T, Saleem A, et al. Choosing an appropriate
inhaler device for the treatment of adults with asthma or COPD.https://www.guidelines.co.uk/respiratory/inhaler-choice-guideline/455503.article2020
11 Vectura. Vectura highlights update made by Hikma on launch of generic
Advair Diskus®.https://ir.q4europe.com/Solutions/VecturaIntranet/3832/newsArticle.aspx?storyid=150363212021
12 Rowex. Package Leaflet: AirBuFo® Forspiro® 160 microgram/4.5
microgram/dose inhalation powder, pre-dispensed. Last Revision April
2018. .https://www.hpra.ie/img/uploaded/swedocuments/2208694.PA0711_284_001.418b6375-936e-4333-b543-e4c22f605a13.000001AirBuFo%20PIL.180731.pdf2018
13 All Party Parliamentary Group on Smoking and Health. Delivering a
Smokefree 2030: The All Party Parliamentary Group on Smoking and Health
recommendations for the Tobacco Control Plan 2021.https://ash.org.uk/about-ash/all-party-parliamentary-group-on-smoking-health/inquiries-reports/deliveringasf2030appgtcp2021/2021
14 Liew K, Wilkinson A. P280 How do we choose inhalers? patient and
physician perspectives on environmental, financial and ease-of-use
factors. Thorax 2017; 72 :A235-A237
15 Fulton O. Tweet about PMI takeover of Vectura.https://twitter.com/just_TUX/status/1426450284851630081?s=202021
16 Cummings KM. A promise is a promise. Tobacco Control 2003;12 :117-118
17 The McKinsey Global Institute. Overcoming obesity: An initial
economic analysis, 2014
18 Hopkinson NS. The path to a smoke-free England by 2030. BMJ2020; 368 :m518
Figure 1 Inhalers listed in the Vectura accounts as generating revenue,
or income from ‘royalty & other marketed revenues’